Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CASP3 | P42574 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28356576 | 0.81 | MAPT (0.55) | SMN1; SMN2MAPTKDM4ENPC1RAB9A | |
| SCHEMBL4207188 | 0.81 | MAPT (0.55) | SMN1; SMN2MAPTKDM4ENPC1RAB9A | |
| SCHEMBL7169212 | 0.81 | HTT (0.52) | SMN1; SMN2HTTALOX15CASP3POLB | |
| SCHEMBL931177 | 0.78 | MAPT (0.57) | SMN1; SMN2MAPTEGFRKDM4ENPC1 | |
| SCHEMBL16881472 | 0.77 | KMT2A (0.62) | SMN1; SMN2HTTALOX15POLBHCAR2 | |
| SCHEMBL1558714 | 0.77 | SMN1; SMN2 (1.00) | SMN1; SMN2HTTALOX15CASP3POLB | |
| SCHEMBL5094634 | 0.77 | KDM4E (0.67) | SMN1; SMN2HTTALOX15CASP3POLB | |
| SCHEMBL6133214 | 0.76 | POLB (0.63) | SMN1; SMN2HTTALOX15CASP3POLB | |
| SCHEMBL2952630 | 0.76 | HTT (1.00) | SMN1; SMN2HTTALOX15POLBHCAR2 | |
| SCHEMBL6118965 | 0.75 | POLB (0.62) | SMN1; SMN2HTTALOX15CASP3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163749-B2 | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL -MEYERS SQUIBB COMPANY | 2009-07-16 | — | — | US | disclosed |
| EP-1966141-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007070818-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | TFPI, F11, F12 | SMN1; SMN2 3646/4885HTT 3327/4885ALOX15 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.